Lung Cancer and Mesothelioma CPG Mini-Module – Managing Stage III Non-Small Cell Lung Cancer (NSCLC)
The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.
In this mini-module, Patrick Forde, MBBCh, of Johns Hopkins Medicine, presents a case on a patient with resectable stage IIIA NSCLC. Dr. Forde and panelists Charu Aggarwal, MD, MPH of the University of Pennsylvania, and Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, then discuss recent developments surrounding the treatment of resectable disease, including how tumor mutation status can inform treatment and the benefits associated with neoadjuvant immunotherapy. This mini-module concludes with a review of treatment options for patients who do not achieve a pathologic complete response after neoadjuvant therapy and resection.
Run Time: 9 Minutes 13 Seconds
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021).
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.